Piperacillin and Tazobactam for Injection

Signal word

DANGER. GHS Class: Serious Eye Damage. Category 1. Respiratory sensitisation. Category 1. Skin Irritation. Category 2. Skin Sensitization. Category 1. Reproductive toxicity. Effects on or via lactation.

Hazard statements

Causes serious eye damage. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Causes skin irritation. May cause an allergic skin reaction. May cause harm to breast-fed children.

Precautionary statements

Obtain special instructions before use. Do not breathe dust/fume/gas/mist/vapours/spray. Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory protection. IF ON SKIN: Wash with plenty of water. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF exposed or concerned: Get medical advice/attention. Immediately call a POISON CENTER or doctor/physician. Specific treatment (see ... on this label). If skin irritation occurs: Get medical advice/attention. If skin irritation or rash occurs: Get medical advice/attention. If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician. Take off contaminated clothing and wash it before reuse. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations. Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Principle Routes of Exposure

Inhalation, Ingestion, Eye contact, Skin Absorption., Injection.

Potential health effects

Eye: Contact with eyes may cause irritation. Skin: May cause skin irritation. Inhalation: May cause irritation of respiratory tract. Ingestion: May cause irritation.

Potential chronic health

Repeat-dose studies up to 6 months in duration employing parenteral routes of exposure (iv and ip) in the rat and dog have established the liver (altered glycogen disposition) and cecum (enlargement) as target organs of toxicity for pip/tazo. (this effect on glycogen distribution is a well-known effect of b- lactamase inhibitors, and the cecal effect is a non-specific effect of antimicrobials in rodents.) other drug-related effects observed in these studies involved changes in red blood cell (rbc), platelet, and serum chemistry parameters. Effects on the rbcs, serum chemistry, and glycogen distribution were reversible or diminished following a recovery period. In studies of fertility and reproductive performance, pip/tazo, administered daily by ip doses, did not affect fertility in rats and was not teratogenic in mice or rats. Postnatal growth, behavior, and reproductive performance of the f1 generation (pups resulting from mating of treated animals) were unaffected by in utero exposure of rats to pip/tazo. Signs/Symptoms: Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Persons who exhibit allergic reactions to any of the penicillin or cephalosporin type antibiotics or to Conditions: other B-Lactamase inhibitors,.